Grace Therapeutics (GRCE) Net Cash Flow (2019 - 2026)

Grace Therapeutics has disclosed Net Cash Flow across 8 years of filings, most recently posting -$3.2 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 51.36% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at -$6.2 million (down 1122.75% YoY), while the FY2026 annual figure was -$5.2 million, down 491.28% from the prior year.
• Net Cash Flow came in at -$3.2 million for Q2 2026 at Grace Therapeutics, down from -$1.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $11.1 million in Q1 2025 to a low of -$8.7 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$3.1 million recorded in 2022.
• Year-over-year, Net Cash Flow jumped 256.33% in 2023 and slumped 179.14% in 2024.
• Over 5 years, Net Cash Flow stood at -$8.7 million in 2022, then grew by 3.18% to -$8.4 million in 2023, then surged by 51.46% to -$4.1 million in 2024, then jumped by 144.15% to $1.8 million in 2025, then tumbled by 277.96% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$3.2 million in Q2 2026, -$1.7 million in Q1 2026, and $1.8 million in Q4 2025.